Wockhardt is planning to raise Rs 1200 crore through issuance of non-convertible debentures (NCDs) on private placement basis. The company will utilise the money to re-pay or pre-pay term loan availed by it and for general corporate purposes. The company will seek shareholders' approval for the same at the upcoming annual general meeting, which will be held on August 13, 2016.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
